alexa Cancer Specific CTL Expansion with ZYX Bioreactor
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Cancer Specific CTL Expansion with ZYX Bioreactor

Yongxin Zhang1*, Ying Wang1, Zhenxiang Wang2, Monica Zhang1 and Zhenying Wang1
1Zyxell Inc. Carrollton, Texas, USA
2Department of Plastic and Aesthetic Surgery, Southwest Hospital, 3rd Military Medical University, Changqing, China
Corresponding Author : Yongxin Zhang
Zyxell Inc, 1452 Halsey Way, Suite 100, Carrollton, Texas 75007, USA
Tel: 9723518317, 9729758600
Fax: 9728207820
Email: [email protected]; [email protected]
Received: January 12, 2016; Accepted: February 29, 2016; Published: February 29, 2016
Citation: Zhang Y, Wang Y, Wang Z, Zhang M, Wang Z (2016) Cancer Specific CTL Expansion with ZYX Bioreactor. J Clin Cell Immunol 7:398. doi:10.4172/2155-9899.1000398
Copyright: © 2016 Zhang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: The use of therapeutic immune cell subsets is becoming an increasingly cost-effective and attractive strategy for the treatment of cancer. Nonetheless, the field of cell therapy is hampered by the inability to consistently generate and expand sufficient numbers of high quality cells from a majority of patients. To address this critical issue, the investigators developed a sophisticated bioreactor technology that maximizes metabolic support and minimizes the damaging shear-stress forces, automatically monitors functional correlates to allow cell harvest at peak functional capacity, and permits cell sorting in situ to minimize cell loss and microbial contamination. In current study, the established cancer-specific CTL expansion system will be tested for its potency of cancer cell killing both in vitro and in vivo.

Methods: To test the cell expansion efficiency of ZYX Bioreactor, the CD8+ T cells expanded in different culture systems were enumerated by flow cytometry and the Cancer-specific cytotoxic T lymphocyte (CTL) activity was measured for their cytokine production and against autologous tumor targets by CTL cytotoxicity assay in vitro and in vivo as well as Annexin V staining to detect low-level cytolytic activity. In the in vivo CTL assay, mouse cancer cell line was used as stimulators and targets for the expanded mouse CTL evaluation in BALB/c mice and human lung cancer cells and expanded human CTL were injected into immunodeficient mice for human CTL evaluation.

Results: In comparison of other cell culture systems, ZYX Bioreactor has significantly higher efficiency in the cancer specific CD8+ T cell expansion, and these CD8+ T cells expanded in ZYX Bioreactor exhibited higher specific CTL cytotoxicity in both in vivo and in vitro studies.

Conclusion: 
ZYX Bioreactor can provide the adequate metabolic support to the growing cancer-specific CD8+ CTLs and the proper condition for the stimulation of cancer cell-carried antigens to the CTLs.  

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords